NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026 12:32
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization458.22 mln
Float35.01 mln
Earnings Date08/12/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.02
Caution advised
1-Year Forecast
42.43
Transformational upside
Relative Strength
18
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-35.11
Deeply negative
Business Description
Upstream Bio Inc. is a clinical-stage company focused on developing new medicines for serious inflammatory conditions, particularly those affecting the airways and lungs. Its lead treatment, verekitug, is currently being tested in clinical trials for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Founded in 2021 and based in Waltham, Massachusetts, the company is working to bring meaningful relief to patients with these difficult-to-treat conditions.
